Study title: A 12-week randomised, double-blind, parallel-group, multicentre phase-III study to compare the efficacy and safety of Symbicort® pMDI (budesonide/formoterol 80/4.5 µg 2 actuations b.i.d., delivered dose) with that of Pulmicort® pMDI (budesonide 100 µg 2 actuations b.i.d., metered dose) and Symbicort Turbuhaler® (budesonide/formoterol 80/4.5 µg 2 actuations b.i.d., delivered dose) in children with asthma
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Respiratory Tract Diseases [C08] | |||||
Brands: | |||||
MAH holders: Please see report | |||||
Assessment: | |||||
Active substance: BUDESONIDE AND FORMOTEROL | |||||
ATC code: | |||||
Document link: SD-039-0716 CSR Synopsis.pdf | |||||
Document date: 2011-09-15 | |||||
Study number: SD-039-0716 | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | Y | Y |